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Abstract: GPR18 is an orphan G protein-coupled receptor (GPCR) expressed in cells of the immune 
system. It is activated by the cannabinoid receptor (CB) agonist A9-tetrahydrocannabinol (THC). 
Several further lipids have been proposed to act as GPR18 agonists, but these results still require 
unambiguous confirmation. In the present study, we constructed a homology model of the human 
GPR18 based on an ensemble of three GPCR crystal structures to investigate the binding modes of 
the agonist THC and the recently reported antagonists which feature an imidazothiazinone core 
to which a (substituted) phenyl ring is connected via a lipophilic linker. Docking and molecular 
dynamics simulation studies were performed. As a result, a hydrophobic binding pocket is predicted 
to accommodate the imidazothiazinone core, while the terminal phenyl ring projects towards an 
aromatic pocket. Hydrophobic interaction of Cys251 with substituents on the phenyl ring could 
explain the high potency of the most potent derivatives. Molecular dynamics simulation studies 
suggest that the binding of imidazothiazinone antagonists stabilizes transmembrane regions TM1, 
TM6  and TM7 of the receptor through a salt bridge between Asp118 and Lys133. The agonist THC is 
presumed to bind differently to GPR18 than to the distantly related CB receptors. This study provides 
insights into the binding mode of GPR18 agonists and antagonists which will facilitate future drug 
design for this promising potential drug target.
Keywords: cannabinoid; docking studies; GPCR; GPR18; MD simulation; orphan GPCRs
1. Introduction
G protein-coupled receptors (GPCR) represent the largest family of membrane proteins in 
eukaryotes. They are structurally characterized by seven transmembrane (TM) regions connected 
by three extracellular (ECL1-3) and three intracellular loops (ICL1-3), an extracellular N-terminal 
and an intracellular C-terminal domain. Upon binding of the cognate agonist (e.g., biogenic amine 
neurotransmitter, nucleotide, lipid, amino acid, peptide, glycoprotein) conformational changes are 
induced. These result in coupling with G proteins, and thereby transducing information from the 
extracellular to the intracellular compartment and inducing or inhibiting downstream signaling 
pathways [1,2]. Despite persistent efforts, nearly 100 GPCRs remain orphan, with their endogenous 
ligands unidentified or unconfirmed [3]. The functionalities and roles of orphan GPCRs under
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(patho)physiological conditions are in most cases poorly understood. The identification of the 
endogenous ligands would be helpful for target validation studies and the design of novel theeapeutic 
drugs for orphan GPCRo.
GPR18 i s such a n o rphan GPCR of the rapeutic inte rest, phyl ogenetically belonging to the 5-branch 
of clafs A, thodopsen-like GPCRs. GPR18 was fire!; described in 1997 and reported to be highly 
cxprceecd ia  different tissues and cell lines of the immune system, including spleen, thymus, cad 
leukocytes [4]. The role of GPR18 is still unclear and controversially debated. GPR18 has been 
proposee by independens groues to be involved in immunological [5-8 ] and neurodegenerative 
processas including;; Alzheimer's disease and moleiple sclerosis [9-1 3 ]. Based ore the observation that 
the octivation of GPRS8  lowers the tntraocular pressure in mice, GPR18 agonists leave been peoposed 
for the treatmeng of glaucoma [C4,d5]. Antagonisgs targeting GPR18 may be effective as anticances 
drugs [16-88L since the receptor was found to be abuneantly overexpdessed in melanoma metastases 
and reported to contribute to Sumor cell sutvival through inhibition of apoptosis [17].
Ia  recent years, several studies tim ed ct the deorphanization of GPR18 have been published. 
Due to the lack of eelective agonists, the modaratelp potent cannabinoid (CB) receptor agonist 
A9-tetrahydrocannabinol (THC, 1) has been used in pharmacological studies to activate human 
GPR18, winch led to the; suggestion to classify G PRm as a cannabinoid receptor subtdpe bBsides CB! 
and CB2 [td-a c ] . N-Arachidonoylglncine (NAGey, 2) and resolvin D2 (RvD2, 3) were pnoposed as 
endogenous agonist3 of GPR18 [ 23,21]. However, independent confirmation for both lipid a i s still 
lacking, as other groups, including ours, have n ot neen able to confirm thefr activation of GPR1 8  [ce,26]. 
We cecently de scribed the first GPR18 anbagonists based on an imidazothi azinone core structure [ 21,e7]. 
These were discovered by screcning a  compound lihrary aa the hpman receptor in a  p-arrestin 
recruitment ensay using enzyme complementation nechnology and THC as an agonist Based on 
ths scseening results, a librory of imidazothiazinones was synthesized and than strudture-activity 
relationships 8SARs) were investigated. PSB-CB-27 (-4) and PSB-CB-5 (5, ioc structures, see F ig u rel)  
were reported as thu first poiont and selective GPR18 antagonists [21].
o
Figure 1. Structures of proposed GPR18 agonists (1-3) and antagonists (4-6).
In the present study, we constructed a homology model of the human GPR18 to elucidate the 
binding mode of the ooly c onfirmed dgonist so far, the natnaal pro duct THC, and o8 oelected antagonists 
by docking and molecular dynamics (MD) simulation studies. Insights into the binding interactions of
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agonists and antagonists will provide a basis for the rational design of more potent ligands and may 
eventually contribute to the deorphanization of GPR18.
2. Material and Methods
2.1. Homology Modeling
The crystal structures of the murine ц-opioid receptor in complex with the agonist BU72 (PDB-ID: 
5C1M), the human P2Yi receptor in complex with the allosteric antagonist BPTU (PDB-ID: 4XNV) 
and the zebrafish lysophosphatidic acid receptor LPA6  in complex with 1-oleoyl-R-glycerol (PDB-ID: 
5XSZ) were obtained from the Research Collaboratory for Structural Bioinformatics (RCSB) Protein 
Data Bank (PDB) [28- 30]. The crystal structures of all three receptors were used as templates for 
generating homology models of the human GPR18 sequence (accession number: Q14330) retrieved 
from the UniProt sequence database (http://www.uniprot.org) [31]. The sequences of the murine 
ц-opioid receptor, the P2YiR, and the zebrafish lysophosphatidic acid receptor LPA6  were aligned 
with that of the human GPR18 using Clustal Omega [32]. We generated 500 models for the human 
GPR18 based on the triple template approach using the standard comparative modeling automodel 
class implemented in MODELLER (version 9.16, University of California, San Francisco, CA, USA). To 
ensure correct tertiary protein structure prediction, we introduced a disulfide bridge between Cys94 
and Cys172. The best model was selected on the basis of Discrete Optimized Protein Energy (DOPE) 
scores calculated for the models [33,34]. The generated models were analyzed, and the best models for 
the human GPR18 were used to perform molecular docking studies, based on the DOPE and GA341 
score, PROSA II Z score, and Ramachandran plots. We took into account that the X-ray crystal structure 
of the lysophosphatidic acid receptor LPA6  is missing part of the ECL2, likely due to low resolution 
and high flexibility of that region. Nevertheless, we decided to include LPA6  as a template for model 
generation as it might provide valuable information, e.g., regarding the transmembrane domains and 
the ligand-binding site. Sequences for the cannabinoid receptors CB1 (P21554) and CB2 (P34972) were 
retrieved from UniProt.
2.2. Docking Studies
Prior to docking, the homology model of the human GPR18 was prepared using the Protein 
Preparation Wizard module implemented in Schrödinger [34,35]. In the first step for protein preparation, 
we preprocessed the structure using the standard protocol at pH 7.4. Docking was performed using 
Induced Fit Docking (IFD) and Glide as implemented in Schrödinger release 2016 [35- 37]. In the first 
step of IFD, Glide ligand docking was performed by removing the side chains of the amino acids in 
the selected binding pocket. In the second phase of docking, Prime was applied to refine the nearby 
residues and to optimize the side chains. In the final docking phase, the ligand was re-docked into all 
induced fit protein structures that were within 30 kcal/mol of the lowest energy structure, by using the 
Glide XP scoring function. A receptor grid center was specified on the basis of preliminary docking 
studies, resulting in the highest docking scores for the centroid of Lys174 with a cubic grid side length 
of 10 A. Preliminary ensemble docking studies provided highest docking scores and consistent SARs 
explanation for this selection as well as comparison with published cannabinoid receptor X-ray crystal 
structures [38].
During the docking simulations, the receptor and the ligands were kept flexible. Following 
docking, the resulting poses of the best model were selected using the IFD scores and Prime Energy 
as representative values. The conformations of the docked ligands within an energy window of 
2.5 kcal/mol were considered. For Glide docking, the following standard parameters were selected: 
receptor van der Waals scaling, 0.50, ligand van der Waals scaling, 0.50, and a maximum of 20 poses 
per ligand. Residues within 5.0 A of the ligand poses were refined, and the side chains were optimized. 
The best docking pose was selected based on the IFD score and Prime Energy values.
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2.3. Compounds
Synthesis of the compounds which are utilized in this computational study as performed in the 
Department of Technology and Biotechnology of Drugs Jagiellonian University at Kraków, Poland, 
and potencies of the compounds were determined at the Department of Pharmaceutical & Medicinal 
Chemistry, Pharmaceutical Institute, University of Bonn, Germany, as previously reported [21,27]. The 
synthesis and biological evaluation of the new potent GPR18 antagonist 6  will be published elsewhere.
2.4. Molecular Dynamics Simulation
We selected several successful MD simulations as starting points for our runs [39- 42]. The GPR18 
complexes and the unbound GPR18 structure were prepared using the method described above to 
determine the protein protonation state at pH 7.4. The obtained structures were processed to the 
CHARMM-GUI molecular simulation program [43- 45]. The forcefield CHARMM36m was applied for 
all simulation runs. Ligand parameters were obtained separately from Schrödinger. The orientation of 
the protein in the phosphatidylcholine lipid bilayer (POPC) was determined using the orientation of 
proteins in membranes (OPM) database [46]. The cubic water box size was adjusted to the structure 
size of 20 A and filled with 0.15 M KCl solution. Water molecules were treated with the transferable 
intermolecular potential with a 3 points (TIP3P) water model [47]. Equilibration steps for all structures 
were divided into six steps using NAMD2 [48]. For the first three steps, we selected a runtime of 250 ps 
in 1 fs intervals. For the last three steps, we selected an equilibration runtime of 2 ns in 2 fs intervals. 
The system was heated from 0 to 303.15 K during equilibration using the NPT ensemble. During 
production stages, the system was kept at 303.15 K. Temperature was regulated using the Langevin 
dynamics thermostat. Production runs were performed for 4 X 50 ns with 4 fs intervals (eventually 
amounting to 200 ns), and frames were collected every 40 ps using ACEMD by Acellera® with the 
NVT ensemble [49].
3. Results
So far, no X-ray crystal structure of GPR18 has been published. After performing a BLAST search, 
three crystal structures with highest sequence identity and overall sequence coverage were chosen 
as templates: the murine q-opioid receptor (PDB-ID: 5C1M) in complex with an agonist, the human 
P2 Y1R (PDB-ID: 4XNV) in complex with an allosteric antagonist, and the zebrafish lysophosphatidic 
acid receptor LPA6  (PDB-ID: 5XSZ) in complex with oleoyl-R-glycerol, showing sequence identities 
of 24.8%, 25.5% and 27.3%, respectively [28- 30,50]. Multiple template approaches had been reported 
to compensate for poor sequence similarity for receptors lacking a template with sequence similarity 
above 30% [51,52]. Therefore, we decided to include all three templates into the process of homology 
modeling, although they represent different states of receptor activation. Structures of class A GPCRs 
belonging to the same 6 -branch as GPR18 (P2Y]_, LPA6 ) andone GPCR that is activated by a lipid like 
GPR18 (LPA6 ) were selected. BBy this approach, we expected to compensate for gaps and mismatching 
residues which would be present in a single template approach. The multiple sequence alignment is 
shown in Figure S1 of Supporting Information.
We subsequently investigated the binding modes of imidazothiazinone antagonists and of the 
agonist THC in the homology model of the human GPR18. To this end, we used the Induced Fit 
module implemented in Maestro Schrödinger to propose a binding mode for the selected ligands and 
to rationalize the potency values obtained in biological studies. Imidazothiazinone derivatives 4 and 5 
were selected as representative potent antagonist structures. In addition to the imidazothiazinone core, 
they both possess a 4-chlorophenoxy substituent connected by a linker which differs in length. For 
the investigated antagonists 4 and 5, IC50 values of 0.650 and 0.279 qM had been determined [21,27]. 
In order to investigate whether the proposed antagonist-GPR18 complexes are stable, we performed a 
200 ns MD simulation study. Furthermore, we rationalized the SARs of related GPR18 antagonists 
using a structure-based approach.
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3.1. Docking Studies o f  Antagonists
Recently, several studies on molecular modeling of the human GPR18 have been published [53- 57]. 
However, neither binding mode predictions of THC (or other agonists) nor MD simulations of >200 ns 
of antagonist-GPR18 complexes have been published so far. Kuder et al. reported molecular modeling 
and docking studies, creating a homology model of the human GPR18 based on the crystal structure of 
the antagonist-bound human P2Yx receptor [53]. The imidazothiazinone group of antagonist 5 was 
predicted to point into a deeper binding pocket towards TM 3 where it was hypothesized to form a 
hydrogen bond with Arg1915'4 2 . The results obtained in the present study indicate a different binding 
mode which is supported by comprehensive SAR data and based on an ensemble of templates for 
homology model generation rather than a single, low homology template as in the previous study [53].
The proposed binding mode for antagonist 4 based on the performed docking studies is presented 
in Figure 2 . Antagonist 4 is predicted to bind in the upper third part of the receptor, extending from 
a hydrophobic cavity formed by ECL2, TM2 and TM3 to an aromatic binding pocket formed by 
TM6  and TM7, which is a common motif for several GPCRs [58- 61]. Compound 4 likely binds with 
its imidazothiazinone moiety close to the conserved disulfide bridge of Cys943 25 and Cys172ECL2. 
Both cysteines and Leu973.28 form a lipophilic binding pocket which is predicted to accommodate 
the thiazine ring. The keto group of the imidazolone ring likely forms an H-bond with Tyr822 64 . 
Due to the close proximity of Arg782'60, cation-n interactions with the imidazolone system are feasible. 
The benzylidene ring may extend towards the center of the receptor, where hydrophobic interactions 
with Thr272739  are possible. The hexyloxy linker could bind with several hydrophobic residues 
(Tyr1604 64, Ile175ECL2, Phe2486 5 1 , M et2757 42) towards an aromatic binding pocket formed by side 
chains of TM6  and TM7. Additional van der Waals forces for hydrophobic interactions with the 
benzylidene moiety and the hexyloxy linker may be provided by the alkyl chain of Lys174ECL2. Several 
aromatic (Phe2486'51, Phe2526-55, Tyr2647-31) and hydrophobic (Cys2516'54 and Leu2556'58) residues of 
TM6  and TM7 are predicted to form the binding pocket accommodating the 4-chlorophenoxy moiety 
of compound 5 (see Figure 3) .
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Figure 2. Proposed binding mode of antagonist 4. (A) Docked pose of 4 in complex with the homology 
model of the hum an GPR18 shown w ith the residues forming the binding; pocket. The receptor is 
displayed in cartoon representation, the amino acid residues (whitel and compound 4 (ofangel are 
shown as steel; models. Oxygen atoms are colored in red, nitrogen atoms in blue, chlorine in green and 
sulfur atoms in yellow. (B) Schematic 2D representation of the binding pocket. Lipophilic amino acids 
are colored in yellow, hydrophilic ones in blue, aromatic ones in red, amino acid residues with mixed 
properties in green. (C) Schematic presentation of the hom ology model of GPR18 in com plex with 
antagonist 4. The imidazothiazinone moiety is predicted to bind in the hydrophobic binding pocket 
consisting of residues of TM3 and ECL2. The 4-chlorophenyl moiety binds in the aromatic binding 
pocket consisting of residues of TM6 and TM7. Cys251 6 54 in the aromatic binding pocket most likely 
interacts with hydrophobic substituents in position 4 of the phenoxy (4) or benzyloxy (5) m oiety of 
the antagonists.
The smaller antagonist 5 can occupy the same binding cavity as antagonist 4 (see Figure 3). The 
imidazothiazinone moiety of both compounds can reach the same binding pose. Due to the missing 
linker, the benzylidine ring is predicted to exhibit an upward shift towards ECL2 where additional 
cation-n interactions with Lys161ECL2 can be realized. In both cases, the chlorine atoms on the terminal 
phenyl ring can reach the same binding cavity consisting of aromatic and hydrophobic residues of 
TM 6  and TM 7 close to Cys2516.54. Therefore, we expect halogen or methyl substitutions to interact 
analogously with Cys2516 54. These findings suggest that hydrophobic substituents in position 4 of 
the terminal phenyl ring of the antagonists are necessary for proper hydrophobic interaction with 
Cys2516'54 resulting in increased potency.
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Figure 3. Proposed binding mode of antagonist 5. (A) Docked pose of 5 in complex with the homology 
model of GPR18 shown with the residues forming; the b inding pocket. (B) Schematic 2D representation 
of the binding pocket. For colo r code, see Figure 2.
3.2. MD Simulation Study o f Antagonists
Both antagonist-GPR18 complexes were stable during the 200 ns MD simulation runs, which 
supports our prediction of the binding pocket based on docking; studies. The duration of the 
MD simulation runs was fn accordance with similar studies performed for other GPCRs [62- 65]. 
The behavior of antag onists 4 and 5 i n the homology m odel of GP R18 during; the 200 ns MD simulftion 
is presented from a bird's eye view percpective in Supplementary Information Figures S2 and S3. 
The 0 ns slate refors to the structure of the docked com plex after equilibration. The cour se of the 
rooS mean iquare deviation (RMSD) indicates that the complex of GPR18 with antagonist 5 reached 
an equilibrated statt aftsr cpproximately 50 in s, and after approximately 100 n s for antagonist: 4 (see 
Figure 4 ). Compared to the unbound GPR18 structure, the complex of GPR18 with antagonist 5
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showed decreased root mean square fluctuation (RMSF) values for TM1, TM2, TM3, TM5 and TM7, 
and for ECL2 and ECL3, indicating stabilization of these regions upon antagonist binding. Similar 
results were observed for the complex with the larger antagonist 4, where decreased RMSF values 
were observed forTM 7, ECL2 and ECL3, and ICL2 and ICL3 when compared to the unbound structure. 
Tire concept of stabilization ef no inaetive conformation oe tho target GPCR upon antagonist binding 
was postulatad for several receptors and supported by mutagenesis experiments, biophysical studies 
and MD simulations [hd^ h - o s ]  This had also been observed for the P2Y! receptor which belongs to 
the same 5 b ran ch  of the class A family of GPCRs. Tire P2Yx receptor cam Ice blocked by structurally 
distinct antagonists (hai bind to different binding sites, the nucleotide analog MRS2500 and the urea 
derivat ive BPTU—both of which stabil ize an i onic lock between an aspartic acid residue of dCL2 and 
an arginine of TMX [09]. During; MD simuiotions for 2 us, RSMD values had been significantly lower 
for the complexeo with an antagonist as compared to tho se with the P2Y! seceptor egonist ADP [69] . 
A  shift in TM3, TM 6  and TM7 in the simulation runs with the agonists crea ted a  void re suliing in 
roceptor activation through a Vulk water influx into thee bindinu pocket [eiS]. Similar observations were 
reported for several class A family nee mber s of GPCRs including g-opioid recepiors and adenosine 
receptors [70-7 3 ].
Figure 4. (a,b) Root mean square deviation (RMSD) curves for the 200 ns MD simulation runs of the 
GPR18 complex with antagonist: 4 (a) and an ta^n io t 5 (b). (c,d) Root mean square fluctua tion (RMSF) 
curves os the molecular dynamics (MD) sim ulation for com pcexes w ith antegonist 4 ic) and 5 (d). 
Curves of the complexes ¡are colored m orango, and the curve os the apoform  of the recep tor m black.
To further investigate conformational changes in the receptor, RMSD values for each 
transmembrane-spanxing helio were calcutateX (see Figure 5). Using the OPM database [46] seven 
transmambrane region segments were determiued: TM1 (Ilel2e1'33-Ser481'58), TM2 (Ile592d)-Phee02'62), 
TM3 (Glu913'22-A la1173-53), TM4 (Val139d43-Tyr160464), TM5 (Ala1835-34-Val2095-60), TM 6  
(Ile2316'34-Phe2546-57) and TM7 (Trp2677-34-Val2897-56). The RMSD values amounted to 2.8, 1.0,
1.2 ,1 .2 ,1 .4, 0.0 and 1 .9 A for TM 1-TM7, respectively, w hen comparing tire TM negions of the comp)lex 
of GPR18 ond compound 4 at 0 ns and at 200 ns. For the complex with the larger antagonist 4, the;
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RMSD values amounted to 2.2, 2 .2 ,1 .4 ,1 .9 , 2.1, 2.3 and 1.8 A for TM 1-TM 7, respectively. The higher 
RMSD values for antagonist 4 can be explained by the size of the compound when compared to 5: 
the larger linker requires adaptation of the receptor, resulting in higher RMSD values. In contrast to 
the behavior of the antagonist-bound complexes, even higher RMSD values were observed for the 
unbound apo form of GPR 18. Here, RMSD values of 4.6,1 .4 ,1 .8 ,2  . 4 .1  .4, 2.9 and 5.4 A were c alculated 
for TM1-TM7, respectively. Furthermore;, the stabilization of TM1, TM6  and TM7 in the presence of an 
antagonist supports the theory of stabilization of an inactive state of the receptor upon binding of an 
antagonist [74- 76].
Apo
PSB-CB-27
PSB-CB-5
50 ns 100 ns 150 ns 200 ns
Figure 5. RMSD valueo for the teanomembrane (TM) regions during the 200 ns MD sim ulation runs.
Values were calculated based on the initial complex sta te after equilibration (0 ns) .
Potential salt bridges within the receptor were analyzed to further investigate the mode of 
inhibition. Arg1193-50 oh the DRY mot if had been proposed to lee located in an "arginine cage," where 
it forms an ionic lock with Asp1183'49, thus stabilizing tire inactive GPR18 [54,77]. Disruption of the 
ionic lock w at postulated -o contuibute to receptor activetion through facilitated movements of TM3 
and TM 6 , resulting. in conformational ohanges towards the intracellular lumen [54]. The authort 
concluded that stable satt bridges or H-bonds induce a  rotamer of Arg119350, which is no longer 
present during; receptor ¡activation. The ionic lock between Asp118349 and Arg119e50 was observed 
in the apo form of GPR18 duoing our 200 ns MD simulation run, which is consistent with previous 
studtes [54]. Interestingly, we observed diffecencec in the behavior of Arg119350 in the apo form as 
compared to the antagonist-bound complexes: in the apo form, tha selt bridge between AraH 93-50 and 
Asp1189-49 foemed after approximately 75 ns and was stable until the end s f the MD simulaiion, while 
no similar interaction was observed for fhe antagonist-bound complexes. A spt18349 formed a stable 
salt bridge with Lys133ICL2 in the complexes but not in the apo form. This lysine is neither conserved in 
the three hornolog;y model templates nor in t ie  two CB recepior subtypes. Furthermore, we obeerved 
stable ionic interactions of Asp85ECL1 wilh Lys22N-terminus and of Asp162ECL2 with Lys161ECL2 in the 
antagonist-bound structures, which were nnt present in ihe apo form. Interaction of Glur31tCL2 with 
Lys1374'ti was observed ire all three structures. The salt bridge between Glu2286'31 and Arg2326'35 
was stable in the receptor apo Worm, which was not the cast for the antagonist-bound structures. 
The erajectory for the salt bridge distances io presented in Supplementary Information -Figure S4).
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We conclude that the binding of an antagonist stabilizes several salt bridges within GPR18, resulting in 
the stabilization of an inactive conformation of the receptor.
We additionally investigated the binding mode of a new potent antagonist, an analog of 4 and 5, 
which has a more rigid substituent in position 4 of the phenyl group (a biphenyl derivative). Compound 
PSB-CB-148 (6 ) contains a p-cyano-biphenyl group which is larger and at the same time less flexible 
than the corresponding substituents in antagonists 4 and 5. The imidazothiazinone group is predicted 
to bind in the same binding cavity as for compounds 4 and 5 (see Figure 6 ). The trajectory of tire 
linker in the docked structure closely resembles the binding; mode of compound 4. Furthermore, 
the proximity of A rg191i42 to both oxygen atoms in the linker indicates bidental H-bond interactions. 
The biphenyl moiety likely binds in a lipophilic binding cavity, where 7T-7T interactions between the 
phtnyl groups and tire aromatic residues Phe2486s*, Phe2526'55 and Tyr2647-31 are; feasible. Interactions 
of the terminal phenyl group with Cys2516'54 are not observed for 6 . Due to its d ecrease! flexibility, 
the terminal group dons not allsw this interaction. The shift in the phenyl group is predicted to place 
the cyano moiety in close; proximity to Asn1805'39. Upon inspection of Asn1855'39, sevoral rotamers 
were found which could form H-bonds with the nitrile (see Figure S5 in Supplementary Information).
Figure 6 . Pioposed binding mode of antagonist 6 . (A) Docked pose of 6 in oomplex with the hom olog. 
model of humnn GPR18 shown with the residues forming the binding pocket. (B) Schematic 2D 
representation yf the binding pocket. For coloo code, see Fcgure 2. (C) Overlay o1 the proposed bmdmg 
modes of GPR18 antagonists. Antagonist 4 is solored in orange, antagonist: 5 in red, antagonisp 6 in blue .
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The obtained data of the docking studies were used to re-analyze the SARs of previously published 
antagonists [21]. The summarized results are presented in Figure 7 (for structures, see Figures S6  and 
S7 in Supporting Information). The linker size was found to have an impact on the potency of the tested 
antagonists. The antagonist containing a hexyloxy linker (4) showed an almost 10-fold increase in 
potency compared to the analog with the shorter ethyloxy linker (7) (IC50 of 0.650 pM versus 5.00 pM). 
Prolongation of the ethyloxy linker resulted in increased inhibitory potency, with hexyloxy being 
optimal (IC50 =  0.650 pM), while larger linkers, i.e., heptyloxy (11) and octyloxy (12), led to slightly less 
potent antagonists (IC50 =  1.71 and 1.15 pM). Our docking results suggest that the hexyloxy linker is 
required for the 4-chlorophenoxy moiety to reach the aromatic binding pocket and to form hydrophobic 
interactions with Cys2516 54. The shorter alkyloxy linker is less well stabilized in the hydrophobic 
cavity formed by Tyr1604'64, Ile175ECL2, Phe2486'51 and Met2757'42. The decrease in potency observed 
for compounds 11 and 12 despite their higher lipophilicity could be explained by limited space in 
the binding cavity or unfavorable adaptation of the alkyloxy linker, resulting in a shifted binding 
position for the 4-chlorophenoxy moiety which prohibits optimal interaction with Cys2516'54. Among 
the smaller compounds missing an additional linker between the benzylidene and the substituted 
phenoxy ring, the most potent antagonists contained a hydrophobic substituent in position 4 of the 
phenyl ring (compounds 5, 14-16). Hydrophobic interactions of substituents in position 4 of the 
phenoxy residue with Cys2516'54 are supported by acceptance of both chlorine and methyl groups in 
compounds 4 and 13, resulting in comparable IC50 values (0.650 and 0.238 pM). The potency (IC50 
values) of the compounds decreased in the following rank order Cl (0.279 pM) >  Br (1.73 pM) >  CH3 
(3.59 pM) >  F (>  10 pM), indicating that the size and lipophilicity of the substituent plays a major 
role. Decreased potency observed for antagonists containing larger substituents in position 4 such as 
ethyl (17) or isopropyl (18) can be explained by the limited space of the binding pocket in proximity 
to Cys2516 54. Moreover, the substitution position on the phenyl ring proved to have an effect on the 
potency of the compounds. Antagonist 19 (o,o-dimethyl-substituted), for example, was inactive (IC50 >  
10 pM). Antagonists containing different heterocycles in place of the imidazothiazinone moiety (20-34) 
showed lower potency as compared to antagonist 5. In our homology model, two aromatic residues 
close to the hydrophobic binding pocket, Tyr812 63 and Trp87ECL1, may form n -n  interactions with 
antagonists containing an additional aromatic group attached to the heterocycle (see Figure S8  in 
Supporting Information). The ethylthio linker connecting the imidazolone ring with the phenyl ring in 
compound 32 might be beneficial to enable proper binding for n -n  interactions. The results suggest 
that the imidazothiazinone heterocycle is optimal to allow hydrophobic packing in the binding pocket 
close to the disulfide bridge of ECL2.
In conclusion, the docking studies, MD simulations and SARs of imidazothiazinones as well as 
antagonists containing smaller heterocycles further support our suggested binding mode of an aromatic 
and lipophilic binding pocket of the human GPR18 for antagonists. The most potent antagonists of 
this series likely interact with Cys2516'54 through lipophilic interactions, and this additional interaction 
is predicted to be the reason for their high potency.
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Figure 7. Schematic representation of the structure-activity relationships (SARs) of GPR18 antagonists.
The diffeeent heterocycles shown contain a 4-chlorophenoxy group, while the compounds with "varying; 
aryl sub stituents and linker lengths contain the imidazothiazinone hetero cycle. Compounds were 
categorized into three groups: highest potency (IC00 <  1 pM), moderate potency (1 pM <  IC50 <  1 0 pM) 
and low potency ((C50 >  1-0 pM) based on their an tago n ist. activity.
3.3. Bin ding Mode o f  TH  C
As a next step, we explored the most likely binding pocket for the GPR18 agonist THC e1). 
The ability of the potent CB receptor agonist THC to activate GPR18 with moderate potency had led to 
the suggestion to classify GPR18 as a novel CB receptor subtype [19]. Lipophilicity is a feature shared 
by GPR18 agonists and antagonists [78,79]. THC is regarded as a promiscuous ligand acting not only 
at cannabinoid but also at several non-cannabinoid receptors [80- 85]. Studies on the binding mode 
of cannabinoids at the cannabinoid receptors CBi and CB2 proposed a binding portal between TM6  
and TM7 from the lipid-facing side of the receptor for the entrance of agonists [8 6 - 8 8 ] . Such entry is 
unique among GPCRs, as ligands typically reach the binding pocket between TM3 and TM7 from the 
extracellular lumen.
To date, two crystal structures of the CB1 receptor bound to THC-related compounds are available 
(PDB-ID: 5XR8, 5XRA) [38]. As observed for many other GPCRs, the agonist binding site, which 
is very lipophilic in the case of the CB1 receptor, is located between a highly conserved Trp6.48 and 
ECL2 [89,90]. The tricyclic THC ring system is stabilized through lipophilic as well as n -n  interactions 
with an aromatic cluster (Phe170Z57, Phe174Z61, Phe177Z64, Phe1893.25, Phe268ECL2, Phe3 797.35). Several 
previous mutagenesis studies have confirmed the key role of the aromatic residues for the binding of 
cannabinoids [38,91- 93]. The alkyl chain of the agonists extends towards a binding cleft formed by 
several lipophilic residues (Leu1933.29, Val1963.32, Tyr275539, Leu2765.40, Leu3596.51 and Met3636.55).
Given the low sequence similarity between the cannabinoid receptors CB1, CB2, and GPR18 (18.7 
and 23.7%, respectively), similar binding of the THC ring system in GPR18 cannot be taken for granted. 
Amino acid residues Val1963 32, Phe268ECL2, Tyr2755 39, Met3636 55 and Phe3797 35 are conserved in 
both CB receptor subtypes but replaced in GPR18 by leucine, serine, arginine, phenylalanine and 
glycine, respectively (see Figure S9 in Supplementary Information for multiple sequence alignment). 
Phe1742.61 and Leu1933.29, but not Leu3596.51, are conserved among all three receptors. The absence of 
the aromatic network responsible for the binding of the THC ring system in the CB receptors suggests 
a different binding mode for the agonist THC at GPR18.
Docking studies of THC were performed using the generated homology model of the human 
GPR18. We observed that THC appears to bind closer to TM4 and TM5 as compared to the cannabinoids
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in the X-ray crystal structures of the CB1 receptor (see Figure 8 ). The phenyl group of the tricyclic 
THC ring system is predicted to bind in a cleft formed by several lipophilic (Val1023 33, Ile175ECL2, 
Phe2486 51, Phe2526 55) and hydrophilic (Lys161ECL2, Lys174ECL2, Asn1885 39, Arg191542, His249652) 
amino acid residues. H-bond interactions are feasible for the oxygen atoms of the chromene moiety 
and Lys161ECL2, as well as the hydroxy group and Asn188539 and Arg1915.42. The cyclohexenyl moiety 
is likely accommodated in a lipophilic binding pocket formed by Thr1524 56, Pro1554 59, Leu1564 60, 
Val184535 and the alkyl side chain of Arg191542. The alkyl group of the agonist likely projects 
towards TM7, where it can be stabilized through lipophilic interactions with Phe2486 51, Phe2526 55 
and Met2757.42. The binding modes of THC in the CB1 receptor as compared to GPR18 are shown in 
Figure S10 of Supporting Information.
Figure 8 . Proposed binding mode of A9-tetrahydrocannabinol (THC) in the homolog7  model of human 
GPR18. (A) The receptor is displayed in cartoon representation, the amino acid residues (white) and 
THC (1, green) are shown as stick models. Oxygen atoms are colored in red, nitrogen atoms in blue, 
sulfur atoms in yellow. (B) Schematic 2D representation of the binding pocket. For color code, see; 
Figure 2.
We propose that the tricyclic THC ring system binds in a bending cavity of GPR18 distan2 to 
the prthosteric blinding; site of the CB1 receptor. The absence of aromptic residues in ECL2 of GPR18 
may' contribute to the proposed shifted binding mode of THC, as n -n  stacking with a phenylalanine 
in position 2.57 is not possible. However, thp binding cleft for the alkyl chain is predicted to be 
ovorlapping in both receptors. It should be pointed out that THC plsplays much higher potenny at CB;; 
(and CB2) receptors as compared to GPR18.
Our results suggest that THC shares a common binding pocket with the imidazothiazinone 
antagonists (see Figure 9). While the imidazothiazinone moiety of the antagonists is predicted to 
bind in a lipophilic pocket formed by amino acid residues of TM2 and TM7, the benzylidene group is 
suggested to project towards the putative binding site of the chromene and alkyl group of THC. This is 
supported by experimental data showing that imidazothiazinone antagonists containing lipophilic 
residues act as competitive antagonists versus THC [21].
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Figure 9. (/A) Comparioon of the proposed binding mode of THC (green) and antagonist 4 (orange) at 
human GPR18. (B) Comparison of the proposed blinding; modes of THC and antagonist 5 (red).
4. Conclusions
Since only approximately 10% of tire non-olfacOory GPCRs are covered by structutal studies, 
meaningful prediction of ligand-binding modes represents one of the greatest challenges i n molecular 
modeling;; [94]. In particular, homo-ogy modeling assessment of receptors with no resolved closely 
related crystal structures requ(res further experimental validation. In the present study, we generated 
a homology model of the orphan GPR18 and predicted the blinding modes of the confirmed agonist 
THC as well as the most potent class- of antagonists oontaining an imidazothiazinone scaf-old. Despite 
tire lack oi olosrly related X-ray crystal structures, we successfully performed docking and MID 
simulation studfes of antagonist complexes which wete in agreement with tire extensive published 
SAR data; The investigated potent antagonists are predicted to share the same binding site for the 
imidazothiazinone core. The linOer of the antagonists is likely accommodated in a lipophilic binding 
clett shared by tCr alkyl chai n of the agonist THC. The 200 ns M D simulation runs suggested stabilization 
of a receptor conformation by antagonists which was not observed for the unbound receptor structure. 
Stabilization of a salt bridge between Asp1183 49 and Lys133ICL2 through imidothiazinone-based 
antagonists may play a role in the inhibition mechanism. Our docking studies suggest a different 
binding mode of the agonist THC in GPR18 as compared to that observed in cannabinoid receptors. 
However, future structural studies will be required to confirm the proposed interactions. The presented 
data provide a well-founded hypothesis that will support the rational design of new ligands for this 
poorly investigated receptor which has potential as a future drug target.
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Structures of GPR18 imidazothiazinone antagonists, Figure S7: Structures of GPR18 antagonists with modification 
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